Evidence map›Paper›PMID 11283046›Full record

ArticleJournal of clinical microbiology2001

Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay.

N Désiré, A Dehée, V Schneider, C Jacomet, C Goujon, P M Girard, W Rozenbaum, J C Nicolas

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Nucleic acid amplification testing using dried blood spots to confirm the diagnosis of HIV-1 in adults.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2024
    Article
  4. Postoperative Bleeding in a HIV-Positive Patient Operated for Oral Cancer: A Case Report.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. EarlierFrontiers in cellular and infection microbiology · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Different human resting memory CD4Science translational medicine · 2020
    Observational
  14. Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

N DésiréService de Microbiologie, Hôpital Rothschild, 33 Boulevard de Picpus, 75571 Paris Cedex 12, France. ndesire@infobiogen.fr
A Dehée
V Schneider
C Jacomet
C Goujon
P M Girard
W Rozenbaum
J C Nicolas
Service de la Santé Publique · CHSorbonne Université · FR

Funding

Wellcome Trust
6 · The paper itself

Abstract

Proviral human immunodeficiency virus type 1 (HIV-1) DNA could be a useful marker for exploring viral reservoirs and monitoring antiretroviral treatment, particularly when HIV-1 RNA is undetectable in plasma. A new technique was developed to quantify proviral HIV-1 using a TaqMan real-time PCR assay. One copy of proviral HIV-1 DNA could be detected with 100% sensitivity for five copies and the assay had a range of 6 log(10). Reproducibility was evaluated in intra- and interassays using independent extractions of the 8E5 cell line harboring the HIV-1 proviral genome (coefficients of variation [CV], 13 and 27%, respectively) and peripheral blood mononuclear cells (PBMC) from a patient with a mean proviral load of 26 copies per 10(6) PBMC (CV, 46 and 56%, respectively). The median PBMC proviral load of 21 patients, measured in a cross-sectional study, was determined to be 215 copies per 10(6) PBMC (range, <10 to 8,381). In a longitudinal study, the proviral load of 15 out of 16 patients with primary infection fell significantly during 1 year of antiretroviral therapy (P = 0.004). In the remaining patient, proviral HIV-1 DNA was detectable but not quantifiable due to a point mutation at the 5' end of the TaqMan probe. No correlation was observed between proviral load and levels of CD4(+) cells or HIV-1 RNA in plasma. TaqMan PCR is sensitive and adaptable to a large series of samples. The full interest of monitoring proviral HIV-1 DNA can now be ascertained by its application to the routine monitoring of patients.

Indexed as

ProvirusesViral LoadAnti-HIV AgentsBase SequenceDNA, ViralDrug Therapy, CombinationGangliaHIV-1HIV InfectionsHumansMolecular Sequence DataPolymerase Chain ReactionRectumReproducibility of ResultsReverse Transcriptase InhibitorsRNA, ViralAnti-HIV AgentsDNA, ViralReverse Transcriptase InhibitorsRNA, ViralTaq Polymerase

Identifiers

PMID11283046
PMCPMC87929
OpenAlexW2160935270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.